The application discloses circRNAs as new biomarkers for the development of heart failure after myocardial infarction； methods for the prediction and diagnosis of heart failure are provided based on measuring said one or more circRNAs； and kits and devices for measuring said circRNAs and/or performing said methods. Further provided are methods for treating patients at risk of heart failure based on the evaluation of said one or more circRNAs.
